Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa

• Main Authors: Sylvie Boyer (Author), Maël Baudoin (Author), Marie Libérée Nishimwe (Author), Melina Santos (Author), Maud Lemoine (Author), Gwenaëlle Maradan (Author), Babacar Sylla (Author), Charles Kouanfack (Author), Patrizia Carrieri (Author), Abbas Mourad (Author), Nicolas Rouveau (Author), Raoul Moh (Author), Moussa Seydi (Author), Alain Attia (Author), Maame Esi Woode (Author), Karine Lacombe (Author)
• Format: Book
• Published: BMC, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Although direct-acting antivirals (DAA) have become standard care for patients with chronic hepatitis C worldwide, there is no evidence for their value for money in sub-Saharan Africa. We assessed the cost-effectiveness of four sofosbuvir-based regimens recommended by the World H...